Mycophenolate revisited

Transplant International

Volumn 28, Issue 5, 2015, Pages 508-515

  Van Gelder, Teun ^a   Hesselink, Dennis A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

generic; mycophenolate mofetil; mycophenolic acid; therapeutic drug monitoring; transplantation

Indexed keywords

AZATHIOPRINE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; ENTERIC COATED TABLET; GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG MONITORING; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); ENTERIC COATED TABLET; GENETIC VARIABILITY; IMMUNOSUPPRESSIVE TREATMENT; PROCEDURES;

AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; DRUGS, GENERIC; GENETIC VARIATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 84928350801     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12554     Document Type: Article

References (68)

1. Matas AJ, Smith JM, Skeans MA, et al.,. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant 2014; 14 (Suppl 1): 11.
2. Smak Gregoor PJ, de Sévaux RG, Ligtenberg G, et al.,. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365.
3. Roodnat JI, Hilbrands LB, Hené RJ, et al.,. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation 2014; 98: 47.
4. Bemelman FJ, de Maar EF, Press RR, et al.,. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009; 88: 421.
5. Moore J, Middleton L, Cockwell P, et al.,. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009; 87: 591.
6. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
7. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
8. Sollinger HW,. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
9. Shapiro R, Jordan ML, Scantlebury VP, et al.,. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411.
10. Johnson C, Ahsan N, Gonwa T, et al.,. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834.
11. Mathew TH,. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450.
12. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296.
13. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 1998; 65: 235.
14. Maripuri S, Kasiske BL,. The role of mycophenolate mofetil in kidney transplantation revisited. Transplant Rev (Orlando) 2014; 28: 26.
15. Ojo AO, Meier-Kriesche HU, Hanson JA, et al.,. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
16. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al.,. Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366.
17. Remuzzi G, Lesti M, Gotti E, et al.,. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004; 364: 503.
18. Remuzzi G, Cravedi P, Costantini M, et al.,. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18: 1973.
19. Knight SR, Russell NK, Barcena L, Morris PJ,. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009; 87: 785.
20. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C,. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39.
21. Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG,. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Investig 2004; 24: 479.
22. Thervet E, Anglicheau D, Legendre C, Beaune P,. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008; 30: 143.
23. Relling MV, Gardner EE, Sandborn WJ, et al.,. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013; 93: 324.
24. Salvadori M, Holzer H, de Mattos A, et al.,. ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
25. Budde K, Curtis J, Knoll G, et al.,. ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237.
26. Budde K, Bauer S, Hambach P, et al.,. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 888.
27. Reinke P, Budde K, Hugo C, et al.,. Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2011; 43: 1641.
28. Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al.,. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation 2011; 92: 426.
29. Sabbatini M, Capone D, Gallo R, et al.,. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009; 23: 617.
30. Cattaneo D, Cortinovis M, Baldelli S, et al.,. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007; 2: 1147.
31. de Winter BC, van Gelder T, Glander P, et al.,. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008; 47: 827.
32. de Winter BC, van Gelder T, Mathot RA, et al.,. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009; 31: 585.
33. Tett SE, Saint-Marcoux F, Staatz CE, et al.,. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) 2011; 25: 47.
34. Capone D, Tarantino G, Kadilli I, et al.,. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant 2011; 26: 3019.
35. Kuypers DR, Le Meur Y, Cantarovich M, et al.,. Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5: 341.
36. Shaw LM, Korecka M, Venkataramanan R, et al.,. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534.
37. van Gelder T, Tedesco Silva H, de Fijter JW, et al.,. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010; 89: 595.
38. Daher Abdi Z, Prémaud A, Essig M, et al.,. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. Clin Pharmacol Ther 2014; 96: 508.
39. Le Meur Y, Büchler M, Thierry A, et al.,. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
40. Le Meur Y, Borrows R, Pescovitz MD, et al.,. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando) 2011; 25: 58.
41. Byrne R, Yost SE, Kaplan B,. Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes? Clin Pharmacol Ther 2011; 90: 204.
42. van Gelder T,. Therapeutic drug monitoring for mycophenolic acid is value for (little) money. Clin Pharmacol Ther 2011; 90: 203.
43. Hazzan M, Labalette M, Copin MC, et al.,. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509.
44. Roelen DL, Doxiadis II, Claas FH,. Detection and clinical relevance of donor specific HLA antibodies: a matter of debate. Transplant Int 2012; 25: 604.
45. Liefeldt L, Brakemeier S, Glander P, et al.,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
46. Bouamar R, Elens L, Shuker N, et al.,. Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8. Transplantation 2012; 93: e39.
47. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE,. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genom 2014; 24: 73.
48. van Gelder T, van Schaik RH, Hesselink DA,. Practicability of pharmacogenetics in transplantation medicine. Clin Pharmacol Ther 2014; 95: 262.
49. Pescovitz MD, Guasch A, Gaston R, et al.,. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003; 3: 1581.
50. Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T,. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transplant Int 2014; 27: 994.
51. van Gelder T, Klupp J, Barten MB, Christians U, Morris RE,. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
52. Hesselink DA, van Hest RM, Mathot RAA, et al.,. Cyclosporine interacts with mycophenolate mofetil by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987.
53. Colom H, Lloberas N, Andreu F, et al.,. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int 2014; 85: 1434.
54. van Gelder T, Silva HT, de Fijter JW, et al.,. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
55. Kuypers DR, Ekberg H, Grinyõ J, et al.,. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet 2009; 48: 329.
56. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al.,. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
57. Sommerer C, Glander P, Arns W, et al.,. Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. Transplantation 2011; 91: 779.
58. Glander P, Sommerer C, Arns W, et al.,. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010; 5: 503.
59. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T,. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309: 1029.
60. Vanhove T, Kuypers D, Claes KJ, et al.,. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transplant Int 2013; 26: 813.
61. Gourishankar S, Houde I, Keown PA, et al.,. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010; 5: 1282.
62. Kiberd BA, Lawen J, Daley C,. Limits to intensified mycophenolate mofetil dosing in kidney transplantation. Ther Drug Monit 2012; 34: 736.
63. de Winter BC, Mathot RA, Sombogaard F, Vulto AG, van Gelder T,. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol 2011; 6: 656.
64. Knoll GA, MacDonald I, Khan A, Van Walraven C,. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
65. Opelz G, Döhler B,. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008; 86: 371.
66. Bremer S, Mandla R, Vethe NT, et al.,. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 2008; 85: 55.
67. van Gelder T, Gabardi S,. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transplant Int 2013; 26: 771.
68. van Gelder T,. ESOT, advisory committee on generic substitution. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transplant Int 2011; 24: 1135.